Mr. Liam Woods:

Overall, we should acknowledge that we are typically talking about new therapies that are beneficial and helpful. The Senator is right in saying that in the early stages of introduction it can appear problematic because we are in dialogue about how to bring those into quick and effective use. In some responses to parliamentary questions recently, we have flagged dialogue with patients and families, and improved and extensive dialogue with patients and families is very important. That is included in our strategic thinking as well as around individual drugs and what assessments might be undertaken in the NCPE.